Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 12 and Allergies (NDA) was asked to provide scientific and technical guidance for the preparation and 13 presentation of applications for authorisation of infant and/or follow-on formula manufactured from 14 protein hydrolysates. This guidance document addresses the information and data to be submitted to 15 EFSA on infant and follow-on formulae manufactured from protein hydrolysates with respect to the 16 safety and suitability of the specific formula and/or the formula's efficacy in reducing the risk of 17 developing allergy to milk proteins. The guidance will be further reviewed and updated with the 18 experience gained from the evaluation of specific applications for authorisation, and in the light of 19 future Community guidelines and legislation. The NDA Panel endorsed this guidance on 13 December 20 2016 for public consultation, to which stakeholders are encouraged to contribute. The document will 21 be revised and updated according to the comments received, where appropriate.
116
In that opinion, EFSA noted that "the safety and suitability of each specific formula containing protein 117 hydrolysates has to be established by clinical studies. Information on protein sources and the 118 technological processes applied should also be provided. In this context, the Panel notes that one 119 particular formula containing partially hydrolysed whey protein has been evaluated for its safety and 
130
As explained in the Regulation's recitals, these requirements may be amended in the future in order to 131 allow the placing on the market of formulae manufactured from protein hydrolysates with a 132 composition different from the one already positively assessed, following a case-by-case evaluation of 133 their safety and suitability by EFSA. In addition, if, after the assessment by EFSA, it is demonstrated 134 that a specific formula manufactured from protein hydrolysates reduces the risk of developing allergy 135 to milk proteins, further consideration will be given to how to adequately inform parents and 136 caregivers about that property of the product.
137
The requirements of Commission delegated Regulation (EU) 2016/127 shall apply to infant formula 138 and follow-on formula manufactured from protein hydrolysates from 2021. The Commission expects 139 that, before that date, dossiers on formulae manufactured from protein hydrolysates will be presented 140 by food business operators for assessment by EFSA with a view to request possible modifications to 141 the conditions applicable to these products in the delegated Regulation.
142
In this context, it is considered necessary to consult EFSA regarding the type of data that food 143 business operators should make available to the Authority in the future, when submitting such 144 dossiers on formulae manufactured from protein hydrolysates. 
145

Terms of reference as provided by the European Commission
162
Objectives 163
The guidance presented in this document is intended to assist applicants in the preparation and 164 presentation of well-structured applications for authorisation of IF and/or FOF manufactured from 165 protein hydrolysates and for assessing the product's efficacy in reducing the risk of developing allergy 166 to milk proteins.
167
It presents a common format for the organisation of the information to be provided and outlines:
168
 the information and scientific data which must be included in the application
169
 the key issues which should be addressed in the application to substantiate the safety and 170 suitability of the formula and/or its efficacy in reducing the risk of developing allergy to milk 171 proteins.
172
It is intended that the guidance will be kept under review, and will be further amended and updated 173 as appropriate in the light of the experience gained in subsequent evaluations.
174
General principles 175 1) In the context of this guidance:
176
Infant means a child under the age of 12 months; 177 Infant formula (IF) means food intended for use by infants during the first months of life and 178 satisfying by itself the nutritional requirements of such infants until the introduction of 179 appropriate complementary feeding;
180
Follow-on formula (FOF) means food intended for use by infants when appropriate 181 complementary feeding is introduced and which constitutes the principal liquid element in a 182 progressively diversified diet of such infants;
183
Hydrolysed formula means an IF or a FOF manufactured from a protein hydrolysate; 184
Control formula means a formula that is used in clinical studies as comparator and meets the 185 2) This guidance presents a common format for the organisation of the information in order to 188 assist the applicant in the preparation of a well-structured application. Adherence to this 189 format will also facilitate easy access to information and scientific data in applications to help 190 the NDA Panel to carry out its evaluation and to deliver its scientific advice in an effective and 191 consistent way.
192
3) It is the duty of the applicant to provide all available scientific data (including data in favour 193 and not in favour) which are pertinent to the application. In its evaluation, the Scientific Panel 221 9) EFSA will make public, once adopted, its scientific opinion on the data and information 222 included in the application, excluding the information considered as confidential. In order to 223 comply with its requirements for transparency as outlined in 
287
Please also highlight the sections in the dossier you consider confidential in another font colour. certify the data. Whenever a quality system is in place for control/documentation (e.g. GLP and 309 ISO17025), the particular system should be indicated.
311
Manufacturing process of the formula 2.2.
312
Please provide a description of the manufacturing process of the formula. This should also contain 313 information about the addition of free amino acids, vitamins, minerals, fats, carbohydrates, and other 314 substances. If the production follows a quality system (e.g. GMP), the particular system should be 315 indicated. If the manufacturing process is claimed as confidential, a non-confidential summary of 316 the manufacturing process should also be provided in the dossier for transparency reasons. 
329
The hydrolysed protein should also be characterised by molecular peptide fingerprinting for 330 identification purposes. The method used for fingerprinting should be described.
331
Information should also be provided on the batch-to-batch variability in relation to the parameters 332 described above.
334
Manufacturing process of the protein hydrolysate 2.4.
335
A detailed description of the procedure used to isolate the starting material, as well as of the 336 manufacturing process of the protein hydrolysate, should be provided. The hydrolytic conditions (e.g. 337 enzymatic/chemical hydrolysis, pH, temperature, duration (hours)) used to produce the hydrolysate 338 should be outlined. Information on degradation products (type and amount) formed during the 339 manufacturing process of the hydrolysate should also be provided.
340
If the production follows a quality system (e.g. GMP), the particular system should be indicated. If the 341 manufacturing process is claimed as confidential, a non-confidential summary of the 342 manufacturing process should also be provided in the dossier for transparency reasons. 
387
If the objective of the study is to detect similarity in growth between the hydrolysed and the control 388 formula, the study should be designed and analysed as an equivalence study using a pre-defined It is acknowledged that, for studies for which the protocol was finalised before adoption of the present 467 guidance, information may not be available for all the items indicated. As a minimum, information 468 should be provided on: infant sex, birth weight in grams, gestation in completed weeks, age at 469 baseline, anthropometry at baseline, date and age at each assessment time point, anthropometry at 470 each assessment time point, feeding history, age at and reasons for withdrawal.
471
Statistical analysis
472
The statistical analysis should be in line with generally accepted scientific principles.
473
Results should be provided for comparisons between the intervention and control groups for all 474 outcome variables assessed. Growth patterns of the study groups should also be compared with 475 accepted growth standards.
476
In particular, the following information should be provided: 
537
At least one randomised, parallel study on the effects of the hydrolysed formula on the incidence of 538 allergy to milk proteins as compared to the control formula is required.
539
The study should be designed as a superiority study in line with generally accepted scientific principles 540 (in particular with respect to randomisation, allocation of subjects to groups, blinding, and sample size 541 calculation).
542
Infants could be enrolled at any time from birth and prior to the introduction of milk proteins other 543 than breast milk. The efficacy of hydrolysed IF and FOF on reducing the risk of developing allergy to 544 milk proteins could be tested in the same study (e.g. hydrolysed IF given before the introduction of 545 complementary feeding; hydrolysed FOF given at the time of introduction of complementary feeding 546 and thereafter).
547
The Panel cannot set specific requirements with respect to the duration of the intervention and/or the 
552
Since factors other than the use of (hydrolysed or control) formula may affect the development of 553 food allergy, including the development of allergic reactions to milk proteins (e.g. breast feeding and data is foreseen, information should be given on how it is planned to assess the robustness of the 777 assumptions made with respect to the imputation of data. For studies for which an adjustment for 778 multiple comparisons is needed in order to preserve the family-wise type I error rate, the pre-planned 779 approach towards adjusting for multiplicity should be specified. In case of studies with an adaptive subjects included in this analysis set could have deviated from the protocol, and the reasons why they 824 were still eligible for inclusion in the PP analysis set. Finally, the reasons for excluding subjects from 825 each analysis at each time point should be given. 
D R A F T
Baseline characteristics of the study group
827
In this section, baseline characteristics for all analysis sets should be given (e.g. ITT, FAS, PP,
